JP2012502047A - 心房細動を治療する方法 - Google Patents

心房細動を治療する方法 Download PDF

Info

Publication number
JP2012502047A
JP2012502047A JP2011526201A JP2011526201A JP2012502047A JP 2012502047 A JP2012502047 A JP 2012502047A JP 2011526201 A JP2011526201 A JP 2011526201A JP 2011526201 A JP2011526201 A JP 2011526201A JP 2012502047 A JP2012502047 A JP 2012502047A
Authority
JP
Japan
Prior art keywords
ranolazine
amiodarone
atrial
administered
per day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011526201A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012502047A5 (enExample
Inventor
チャールズ アンツェレビッチ，
アレキサンダー バラシュニコフ，
ジョン シュライオック，
スリダーラン ラジャマニ，
ルイス ベラーディネリ，
Original Assignee
ギリアード サイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ギリアード サイエンシーズ， インコーポレイテッド filed Critical ギリアード サイエンシーズ， インコーポレイテッド
Publication of JP2012502047A publication Critical patent/JP2012502047A/ja
Publication of JP2012502047A5 publication Critical patent/JP2012502047A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011526201A 2008-09-04 2009-09-03 心房細動を治療する方法 Pending JP2012502047A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9435908P 2008-09-04 2008-09-04
US61/094,359 2008-09-04
US10877608P 2008-10-27 2008-10-27
US61/108,776 2008-10-27
PCT/US2009/055924 WO2010028173A2 (en) 2008-09-04 2009-09-03 Method of treating atrial fibrillation

Publications (2)

Publication Number Publication Date
JP2012502047A true JP2012502047A (ja) 2012-01-26
JP2012502047A5 JP2012502047A5 (enExample) 2012-10-18

Family

ID=41421639

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011526201A Pending JP2012502047A (ja) 2008-09-04 2009-09-03 心房細動を治療する方法

Country Status (5)

Country Link
US (1) US20100056536A1 (enExample)
EP (1) EP2337559A2 (enExample)
JP (1) JP2012502047A (enExample)
CA (1) CA2735653A1 (enExample)
WO (1) WO2010028173A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ536678A (en) * 2002-05-21 2007-01-26 Cv Therapeutics Inc Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
CA2761771A1 (en) * 2009-05-14 2010-11-18 Gilead Sciences, Inc. Ranolazine for the treatment of cns disorders
CN102725290B (zh) * 2009-07-27 2016-03-09 吉利德科学股份有限公司 作为离子通道调节剂的稠合杂环化合物
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
ES2529119T3 (es) 2010-07-02 2015-02-17 Gilead Sciences, Inc. Compuestos heterocíclicos condensados como moduladores de canales iónicos
TWI510480B (zh) 2011-05-10 2015-12-01 Gilead Sciences Inc 充當離子通道調節劑之稠合雜環化合物
NO3175985T3 (enExample) 2011-07-01 2018-04-28
TWI549944B (zh) 2011-07-01 2016-09-21 吉李德科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
US20140364417A1 (en) * 2013-05-03 2014-12-11 Gilead Sciences, Inc. Method of treating atrial fibrillation
CA2934517C (en) 2013-12-19 2018-10-16 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
WO2017147328A1 (en) 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
CA3016081A1 (en) 2016-03-04 2017-09-08 Gilead Sciences, Inc. Compositions and combinations of autotaxin inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005528393A (ja) * 2002-04-04 2005-09-22 シーブイ・セラピューティクス・インコーポレイテッド 不整脈の治療法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US6221903B1 (en) * 1999-01-11 2001-04-24 University And College Of Nevada, Reno Amiodarone as an antifungal agent
EP2117509A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005528393A (ja) * 2002-04-04 2005-09-22 シーブイ・セラピューティクス・インコーポレイテッド 不整脈の治療法

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN6013060420; ＰＡＣＥ Ｖｏｌ．３１，　Ｎｏ．６, 200806, ｐ．７６５-７６８ *
JPN6013060423; Ｐｒｏｇ．　Ｍｅｄ． Ｖｏｌ．２７，　ｓｕｐｐｌ．２, 2007, ｐ．２７６０-２７６４ *
JPN6013060425; Ｐｒｏｇ．　Ｍｅｄ． Ｖｏｌ．２７，　ｓｕｐｐｌ．２, 2007, ｐ．２７２９-２７３２ *
JPN6013060429; Ｊａｐａｎｅｓｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｅｌｅｃｔｒｏｃａｒｄｉｏｌｏｇｙ Ｖｏｌ．２７，　Ｎｏ．３, 2007 *
JPN6013060432; Ａｎｎａｌｓ　ｏｆ　ｔｈｅ　Ｎｅｗ　Ｙｏｒｋ　Ａｃａｄｅｍｙ　ｏｆ　Ｓｃｉｅｎｃｅｓ Ｖｏｌ．１１２３, 200803, ｐ．１０５-１１２ *
JPN6013060435; Ｊ．　Ｃａｒｄｉｏｖａｓｃ．　Ｐｈａｒｍａｃｏｌ． Ｖｏｌ．５２，　Ｎｏ．２, 200808, ｐ．１２１-１２８ *
JPN6013060437; 臨床と研究 Ｖｏｌ．８３，　Ｎｏ．１０, 2006, ｐ．１４５５-１４５８ *
JPN6013060439; Ｐｒｏｇ．　Ｍｅｄ． Ｖｏｌ．２５，　ｓｕｐｐｌ．１, 2005, ｐ．１５６１-１５６５ *

Also Published As

Publication number Publication date
CA2735653A1 (en) 2010-03-11
WO2010028173A3 (en) 2010-11-04
WO2010028173A2 (en) 2010-03-11
EP2337559A2 (en) 2011-06-29
US20100056536A1 (en) 2010-03-04

Similar Documents

Publication Publication Date Title
JP2012502047A (ja) 心房細動を治療する方法
AU2010339753B2 (en) Method of treating atrial fibrillation
TWI519298B (zh) 決奈達隆（ｄｒｏｎｅｄａｒｏｎｅ）於製備用於預防心血管疾病住院或死亡之藥劑之用途
KR20110026422A (ko) 영구적 심방 세동의 예방을 위한 드로네다론
JP2018528251A (ja) 心房細動の予防及び治療のためのドフェチリドとメキシレチンの組合せ
Advani et al. Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol
CA2727210A1 (en) Dronedarone for the prevention of cardioversion
JP7137852B2 (ja) ９‐β‐Ｄ‐アラビノフラノシルヒポキサンチンによる不整脈治療
AU2014274638B2 (en) Method of treating atrial fibrillation
CN104363906B (zh) 去乙基胺碘酮组合物
Schneeweiss et al. Ethmozine
HK1155668A (en) Dronedarone for the prevention of permanent atrial fibrillation
HK1197535A (en) Method of treating atrial fibrillation
HK1170675B (en) Method of treating atrial fibrillation
HK1197535B (en) Method of treating atrial fibrillation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140304

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140404

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141219